UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: January, 2005
Commission File Number: 000-50393
NEUROCHEM INC.
275 Armand-Frappier Boulevard
Laval, Quebec
H7V 4A7
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40 F. Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
January 28, 2005
By: /s/ David Skinner
---------------------------------------
David Skinner
General Counsel and Corporate Secretary
NEUROCHEM INC.
MATERIAL CHANGE REPORT
----------------------
1. NAME AND ADDRESS OF ISSUER
Neurochem Inc. (the "NEUROCHEM")
275 Armand-Frappier Blvd.
Laval, QC H7V 4A7
2. DATE OF MATERIAL CHANGE
January 20, 2005
3. NEWS RELEASE
A press release was issued on January 20, 2005 by Neurochem in Laval, Quebec.
4. SUMMARY OF MATERIAL CHANGE
On January 20, 2005, Neurochem announced senior management appointments and
reassignments of responsibility.
5. FULL DESCRIPTION OF MATERIAL CHANGE
On January 20, 2005, Neurochem announced the renewed commitment by Francesco
Bellini, Chairman and CEO, to remain with the Company in an executive capacity
for at least three more years. Dr. Bellini also assumes the office of President.
This commitment was evidenced by the three year renewal of the management
services agreement between Neurochem and Picchio International Inc., by virtue
of which the services of Francesco Bellini are provided to Neurochem. At the
same time, Neurochem announced the appointment of two new members to its senior
management team as well as other changes at the senior management level.
Joining Neurochem are Shona McDiarmid, PhD, Vice President - Intellectual
Property, and Daniel Delorme, PhD, as Vice President - Research. Philippe
Calais, Pharm. D., currently President, is appointed President - Global
Business, and Denis Garceau, PhD, Vice President - Drug Development, becomes
Senior Vice President, Drug Development. Francine Gervais, PhD, Vice President,
Research and Development, will be leaving Neurochem but will remain a consultant
to Neurochem.
Dr. Shona McDiarmid is a lawyer who brings to Neurochem more than fifteen years
experience securing and defending intellectual property rights in the
pharmaceutical, medical and biotechnology fields. Dr. McDiarmid began her career
in intellectual property at Bereskin & Parr in Toronto, where she practiced
intellectual property law with a focus on biotechnology and pharmaceutical
patents and related litigation. In 1996 she joined BioChem Pharma as Director of
Intellectual Property, where she managed an extensive international patent
portfolio in core fields, including CNS, antivirals, anti-infectives, oncology,
biologics and vaccines. Following the merger of BioChem Pharma with Shire
Pharmaceuticals Group in 2001, Dr. McDiarmid was
-2-
promoted to Vice President of Global Intellectual Property for the Shire
Pharmaceuticals Group. Dr. McDiarmid holds a PhD in biology from the University
of Western Ontario, and a law degree from the University of Ottawa. Dr.
McDiarmid is also a member of the Ontario Bar and a registered Canadian patent
agent.
Dr. Daniel Delorme has almost 20 years experience in biotechnology and
pharmaceutical companies. Prior to joining Neurochem, he served between 2003 and
2005 as Vice President, Research and Development, at the Canadian
biopharmaceutical company Phagetech Inc. and from 1998 to 2003, Dr. Delorme was
Vice President Medicinal Chemistry at MethylGene Inc. From 1995 to 1998, Dr.
Delorme served as Associate Director at AstraZeneca, Montreal, and prior to that
as a Research Fellow at Merck-Frosst. He is the co-inventor of 33 US patents and
patent applications and the author of 42 scientific papers. Dr. Delorme received
his doctoral degree in Organic Chemistry from the Universite de Montreal.
The responsibilities of Dr. Calais as President, Global Business, will encompass
the establishment of Neurochem's international marketing and sales operations in
North America and Europe and the management of collaborative activities with
business partners.
With his nomination, Dr. Garceau will be adding to his current role in drug
development, a more active participation in determining Neurochem's strategic
scientific direction.
6. CONFIDENTIALITY
Not applicable.
7. OMITTED INFORMATION
None.
8. EXECUTIVE OFFICER
For further information, please contact Lise Hebert, Vice-President, Corporate
Communications, at (450) 680-4572.
DATED this 27th day of January, 2005.
NEUROCHEM INC.
By: (signed) Lise Hebert
------------------------------------------
Lise Hebert,
Vice-President, Corporation Communications